retatrutide type 2 diabetes phase 2 results 2024 2025 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Retatrutide UK Guide: Key Facts

RESEARCH REFERENCES Jastreboff AM, et al

Graphical Abstract Similar content being viewed by others Introduction Glucagon is one of the bodys principal blood glucose-increasing (hyperglycaemic) hormones [1]

As a dual agonist, it targets both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors

You could also add more bacteriostatic water to bring the concentration to your intended level

Using telehealth platforms like ShapeIn RX is also a wonderful way to access online GLP-1 medications

2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD)